Agios Pharmaceuticals (AGIO) Common Equity (2012 - 2026)

Agios Pharmaceuticals' Common Equity history runs 15 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• Quarterly Common Equity fell 24.37% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (down 24.37% YoY) and the FY2025 annual result came in at $75000.0, down 100.0% from the prior year.
• Common Equity was $1.1 billion for Q1 2026 at Agios Pharmaceuticals, up from $75000.0 in the prior quarter.
• Across five years, Common Equity topped out at $1.6 billion in Q3 2024 and bottomed at $75000.0 in Q4 2025.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2022 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 107.35% in 2025, while the deepest fall reached 100.0% in 2025.
• Agios Pharmaceuticals' Common Equity stood at $1.1 billion in 2022, then dropped by 26.33% to $811.0 million in 2023, then soared by 90.0% to $1.5 billion in 2024, then sank by 100.0% to $75000.0 in 2025, then jumped by 1478720.0% to $1.1 billion in 2026.
• Business Quant data shows AGIO's Common Equity at $1.1 billion in Q1 2026, $75000.0 in Q4 2025, and $1.3 billion in Q3 2025.